Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Oculis Holding AG Ordinary shares(OCS)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for OCS
09/25/2026: OCS (1-star) is currently NOT-A-BUY. Pass it for now.
Oculis Holding AG is a clinical-stage biopharmaceutical company specializing in topical treatments for eye conditions. Its main strength lies in its proprietary OPTIREACH platform, which aims to provide non-invasive alternatives to traditional, often painful, ocular injections. The primary investment opportunity is the potential market disruption of its late-stage candidates like OCS-01 in large disease areas. However, as a pre-commercial company, it faces significant risks, including clinical trial failure, regulatory hurdles, and intense competition from established pharmaceutical giants. This stock may suit risk-tolerant growth investors who can monitor binary clinical developments and the company's ongoing cash runway requirements.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Investors seeking high-potential exposure to disruptive biotechnology breakthroughs may find the pipeline compelling. |
| Momentum investor | Mixed fit | Momentum potential is high during clinical trial catalysts, but trading requires monitoring for positive study outcomes. |
| Value investor | Weak fit | The lack of current earnings makes standard valuation metrics like P/E inapplicable for this investment. |
| Dividend investor | Weak fit | The company does not pay dividends and focuses all cash on growth. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology stocks carry high binary risk and significant price volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stock prices are highly sensitive to clinical trial outcomes and regulatory news cycles. |
| Valuation risk | Medium / high | Valuation is speculative as it depends entirely on the future commercial success of unapproved pipeline assets. |
| Competition risk (large pharmaceutical incumbents) | High | Well-capitalized competitors can easily challenge new entrants with established market dominance. |
| Business quality | Medium | The company is early-stage, meaning its commercial-grade franchise is not yet established. |
| Dividend income | Low / none | No capital return is provided via dividends. |
| Execution risk | High | Success requires perfect navigation of complex clinical trials and regulatory approval processes. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 21.14% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 514.74M USD | Price to earnings Ratio - | 1Y Target Price 36.61 |
Price to earnings Ratio - | 1Y Target Price 36.61 | ||
Volume (30-day avg) 183.7K shares | Beta 0.23 | 52 Weeks Range 9.10 - 34.48 | Updated Date 09/25/2026 |
52 Weeks Range 9.10 - 34.48 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.68 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Ophthalmic R&D | Clinical trial development and potential future licensing of patented drug candidates. | The company currently spends money rather than making profit, with long-term revenue dependent on successfully bringing eye medication to market. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 278.59M | Price to Sales(TTM) 438.83 |
Enterprise Value 278.59M | Price to Sales(TTM) 438.83 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.47 | Shares Outstanding 55.53M | Shares Floating 52.41M |
Shares Outstanding 55.53M | Shares Floating 52.41M | ||
Percent Insiders 3.53 | Percent Institutions 47.55 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Oculis Holding AG Ordinary shares
Exchange NASDAQ | Headquarters - | ||
IPO Launch date 2023-03-02 | CEO & Director Dr. Riad Sherif M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://oculis.com |
Full time employees 60 | Website https://oculis.com | ||
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.